| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6875872 | HORIZON | Compounds |
May, 2014
(9 years ago) | |
| US5900424 | HORIZON | Omeprazole magnesium salt form |
May, 2016
(7 years ago) | |
| US6369085 | HORIZON | Form of S-omeprazole |
May, 2018
(5 years ago) | |
| US7411070 | HORIZON | Form of S-omeprazole |
May, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6875872 (Pediatric) | HORIZON | Compounds |
Nov, 2014
(9 years ago) | |
| US5714504 | HORIZON | Compositions |
Feb, 2015
(9 years ago) | |
|
US5714504 (Pediatric) | HORIZON | Compositions |
Aug, 2015
(8 years ago) | |
|
US5900424 (Pediatric) | HORIZON | Omeprazole magnesium salt form |
Nov, 2016
(7 years ago) | |
| US7745466 | HORIZON | Form of S-omeprazole |
Oct, 2018
(5 years ago) | |
|
US7411070 (Pediatric) | HORIZON | Form of S-omeprazole |
Nov, 2018
(5 years ago) | |
|
US6369085 (Pediatric) | HORIZON | Form of S-omeprazole |
Nov, 2018
(5 years ago) | |
| US8557285 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(1 year, 10 months ago) | |
| US8858996 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDS |
May, 2022
(1 year, 10 months ago) | |
| US8852636 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(1 year, 10 months ago) | |
| US9198888 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(1 year, 10 months ago) | |
| US9161920 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(1 year, 10 months ago) | |
| US9707181 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(1 year, 10 months ago) | |
| US9345695 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(1 year, 10 months ago) | |
| US6926907 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
Feb, 2023
(1 year, 1 month ago) | |
| US9393208 | HORIZON | Method for delivering a pharmaceutical composition to patient in need thereof |
Sep, 2029
(5 years from now) | |
| US9220698 | HORIZON | Method for delivering a pharmaceutical composition to patient in need thereof |
Mar, 2031
(6 years from now) | |
| US8945621 | HORIZON | Method for treating a patient at risk for developing an NSAID-associated ulcer |
Oct, 2031
(7 years from now) | |
Vimovo is owned by Horizon.
Vimovo contains Esomeprazole Magnesium; Naproxen.
Vimovo has a total of 22 drug patents out of which 19 drug patents have expired.
Expired drug patents of Vimovo are:
- US6875872*PED
- US5714504
- US5714504*PED
- US5900424*PED
- US7745466
- US7411070*PED
- US6369085*PED
- US8557285
- US8858996
- US8852636
- US9198888
- US9161920
- US9707181
- US9345695
- US6926907
- US6875872
- US5900424
- US6369085
- US7411070
Vimovo was authorised for market use on 30 April, 2010.
Vimovo is available in tablet, delayed release;oral dosage forms.
Vimovo can be used as risk-reduction of nsaid-associated gastric ulcers in patients also taking low dose aspirin, risk-reduction of nsaid-associated gastric ulcer in patients requiring nsaid treatment, risk-reduction of nsaid-associated gastric ulcer, relief of signs and symptoms of arthritis and risk-reduction of nsaid-associated gastric ulcer, risk-reduction of nsaid gastric ulcer in patients requiring chronic nsaid treatment.
The generics of Vimovo are possible to be released after 17 October, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 06, 2020 |
| New Combination(NC) | Apr 30, 2013 |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM; NAPROXEN ingredient
Market Authorisation Date: 30 April, 2010
Treatment: Risk-reduction of nsaid-associated gastric ulcer; Relief of signs and symptoms of arthritis and risk-reduction of nsaid-associated gastric ulcer; Risk-reduction of nsaid-associated gastric ulcer in pa...
Dosage: TABLET, DELAYED RELEASE;ORAL
VIMOVO family patents
